A Randomized, Open-label, Single Dose, Crossover Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393(2) in Healthy Volunteers Under Fed Conditions
Latest Information Update: 05 Jul 2022
At a glance
- Drugs CKD-393 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Chong Kun Dang
- 27 Jun 2022 Status changed from recruiting to completed.
- 28 Apr 2022 New trial record